COVID-19 Thlopnak “Remdesivir” Sii Hneksaknak an Ngol Lai, Serchuahnak Lei Tu ah Thazaang an Chuah Cang Lai

| The Chin Journal | Hakha, Chin State

COVID-19 zawtnak thlop nakding ca ah Remdesivir sii hnesknak an tuahmi cu May thla dih ah an ngol cang lai, tiah theih a si.

“Remdesivir” sii cu US ram, California ah a ummi Gilead Sciences nih a serchuahmi a si i,  January 2020 khan hneksaknak tuah hram an rak thawk.

COVID-19 mizaw lakhruak (Emergency) in thlop a herhmi pawl ca ah hman ding in US FDA nih May 1 ah khan nawl zong a rak onh cang.

US FDA nih nawl a onh hnu ah hneksaknak an tuah cuahmahmi cu hun ngol i sii serchuahnak le phawtzamhnak lei tu ah ttuanhma lak ding in timhtuahnak an ngei, tiah Reuters nih a langhter.

April thlathawh lei ah khan Johns Hopkins University nih “Remdesivir” sii hi atu tiang ah cun COVID-19 thlopnak ca ah ruahchannak a um bikmi sii a si ko, tiah a rak ti.

Cu lawng si loin February 2020 ah WHO nih “Remdesivir” sii hi COVID-19 thlopnak ca ah thilti khawhnak a ngei tiah kan hmuh, tiah a rak ti bal ve.

Remdesivir sii hneksaknak ah haotu a simi Dr. Kathleen Mullane nih, “Hneksaknak ah kan thlopmi mizaw tam u hi a zualhma ngaimi an si hna. Ni 6 chung ah an dam i sizung in an ttum. Cucaah, hi sii hmang hin ni 10 hlan ah thlop khawh an si,” tiah a chim.

Sihmanhsehlaw, Remdesivir sii hman ruang ah hnehnu damlonak pakhatkhat (Side Effect) a chuahtermi a um le um lo fiang in fehter khawh a si rih lo caah lakhruak piin hman awk ah a thin a phangmi sibawite zong an um len ve.

US’s Department of Health and Human Services nih, “US ramchung sizung pawl ca ah Gilead Sciences nih Remdesivir sii dur 6o7,000 a chuah hmasa lai. Cu chung ah cun 40% hi cu an hlutmi a si. Mizaw 78,000 kan thlop khawh hna lai,” tiah a langhter.

Latest News

News in Burmese